Effect of Olopatadine on Allergic Tear Mediators
Expression of Inflammatory Mediators in Allergic Conjunctivitis
2 other identifiers
interventional
21
1 country
1
Brief Summary
The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2000
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2000
CompletedFirst Submitted
Initial submission to the registry
December 26, 2007
CompletedFirst Posted
Study publicly available on registry
February 6, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2009
CompletedResults Posted
Study results publicly available
September 20, 2018
CompletedSeptember 20, 2018
August 1, 2018
9.2 years
December 26, 2007
June 22, 2012
August 23, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine Treatment) Promotes Eosinophil Adhesion
Outcome: The collected tears (from 10 subjects)were pooled, incubated with primary conjunctival epithelial cells before eosinophil adhesion was measured via eosinophil peroxidase assay. Eosinophils in eosinophils / square cm measured.
1 week for tear collection, tears stored at - 80 C until used
Study Arms (1)
Olopatadine
EXPERIMENTALone drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
Interventions
Eligibility Criteria
You may qualify if:
- Skin test positive
- Able to put drops in eyes
- Able to have tears collected
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Wisconsin, Madisonlead
- National Eye Institute (NEI)collaborator
Study Sites (1)
University of Wisconsin
Madison, Wisconsin, 53705, United States
Related Publications (2)
Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol. 2004 Oct;4(5):441-5. doi: 10.1097/00130832-200410000-00018.
PMID: 15349046BACKGROUNDCook EB, Stahl JL, Brooks AM, Graziano FM, Barney NP. Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3423-9. doi: 10.1167/iovs.06-0088.
PMID: 16877412RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Jim Stahl, PhD
- Organization
- University of Wisconsin-Madison
Study Officials
- PRINCIPAL INVESTIGATOR
Neal P Barney, MD
University of Wisconsin, Madison
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 26, 2007
First Posted
February 6, 2008
Study Start
September 1, 2000
Primary Completion
November 1, 2009
Study Completion
November 1, 2009
Last Updated
September 20, 2018
Results First Posted
September 20, 2018
Record last verified: 2018-08